Highlights and Quick Summary
- Capex/Depreciation for the quarter ending June 29, 2021 was -0.09 (a 4.36% increase compared to previous quarter)
- Year-over-year quarterly Capex/Depreciation decreased by -6.44%
- Annual Capex/Depreciation for 2020 was -0.12 (a -54.95% decrease from previous year)
- Annual Capex/Depreciation for 2019 was -0.27 (a -24.29% decrease from previous year)
- Annual Capex/Depreciation for 2018 was -0.36 (a 2.58% increase from previous year)
- Twelve month Capex/Depreciation ending June 29, 2021 was -0.1 (a -5.38% decrease compared to previous quarter)
- Twelve month trailing Capex/Depreciation decreased by -27.81% year-over-year
Trailing Capex/Depreciation for the last four month:
|29 Jun '21||30 Mar '21||30 Dec '20||29 Sep '20|
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Capex/Depreciation of AbbVie Inc.Most recent Capex/Depreciationof ABBV including historical data for past 10 years.
Interactive Chart of Capex/Depreciation of AbbVie Inc.
AbbVie Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)
Business Profile of AbbVie Inc.
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.